Skip to contentH
Heron Therapeutics, Inc.
H
HRTXHeron Therapeutics, Inc. Q1 2024 · 10-Q
Revenue$34.67M$34.67M+17.1% vs Q1 2023 Net Income-$3.16M-$3.16MN/M vs Q1 2023 EPS Diluted-$0.02-$0.02N/M vs Q1 2023 Gross Profit$26,226,000+105.5% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Heron Therapeutics, Inc. · CIK 818033 · Engraved from SEC EDGAR
Operating Cash Flow-$9,516,000N/M Margins · derivedGross margin75.6%+32.6 pt vs Q1 2023
Operating margin-13.8%+97.8 pt vs Q1 2023
Net margin-9.1%+101.5 pt vs Q1 2023
ended Mar 31, 2024 · filed May 7, 2024 · 37 d after period end